Academic Journal
View in EDS

Diabetic kidney disease treatment: new perspectives

Bibliographic Details
Title: Diabetic kidney disease treatment: new perspectives
Authors: Li-Li Tong, Sharon G. Adler
Source: Kidney Research and Clinical Practice, Vol 41, Iss Suppl 2, Pp S63-S73 (2022)
Publisher Information: The Korean Society of Nephrology, 2022.
Publication Year: 2022
Collection: LCC:Internal medicine
LCC:Specialties of internal medicine
Subject Terms: chronic kidney diseases, diabetic kidney disease, end-stage kidney disease, glucagon-like peptide-1 receptor, mineralocorticoid receptor antagonists, renin-angiotensin-system, sodium-glucose transporter 2 inhibitors, Internal medicine, RC31-1245, Specialties of internal medicine, RC581-951
More Details: Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease and end-stage kidney disease worldwide, as the obesity epidemic and the burden of diabetes continue to rise globally. In general, guideline management of patients with DKD recommends lifestyle modifications, blood pressure and glycemic control, and dyslipidemia treatment along with other cardiovascular disease risk reduction measures. The inhibition of the renin-angiotensin system (RAS) using an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker remains the foundational therapy for DKD. In type 2 diabetes (T2D), significant advances in therapeutics, including the sodium-glucose cotransporter-2 inhibitors (SGLT2i), the glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the nonsteroidal mineralocorticoid receptor agonist (MRA) finerenone, have dramatically expanded the armamentarium for treating DKD and its cardiovascular complications. Initiating, optimizing, and sustaining evidence-based pharmacological therapy using a therapeutic combination of RAS inhibitor + SGLT2i/GLP-1 RA + nonsteroidal MRA + statin is likely to significantly improve outcomes for T2D with DKD. Research into potential novel therapeutic targets for DKD remains particularly active and brings much anticipation and optimism to this field.
Document Type: article
File Description: electronic resource
Language: English
Korean
ISSN: 2211-9132
2211-9140
Relation: http://www.krcp-ksn.org/upload/pdf/j-krcp-21-288.pdf; https://doaj.org/toc/2211-9132; https://doaj.org/toc/2211-9140
DOI: 10.23876/j.krcp.21.288
Access URL: https://doaj.org/article/682ffe0ab0b745c0956623929112495d
Accession Number: edsdoj.682ffe0ab0b745c0956623929112495d
Database: Directory of Open Access Journals
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edsdoj&genre=article&issn=22119132&ISBN=&volume=41&issue=Suppl%202&date=20220901&spage=S63&pages=&title=Kidney Research and Clinical Practice&atitle=Diabetic%20kidney%20disease%20treatment%3A%20new%20perspectives&aulast=Li-Li%20Tong&id=DOI:10.23876/j.krcp.21.288
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
  – Url: https://doaj.org/article/682ffe0ab0b745c0956623929112495d
    Name: EDS - DOAJ (s8985755)
    Category: fullText
    Text: View record from DOAJ
    MouseOverText: View record from DOAJ
Header DbId: edsdoj
DbLabel: Directory of Open Access Journals
An: edsdoj.682ffe0ab0b745c0956623929112495d
RelevancyScore: 947
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 947.154418945313
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Diabetic kidney disease treatment: new perspectives
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Li-Li+Tong%22">Li-Li Tong</searchLink><br /><searchLink fieldCode="AR" term="%22Sharon+G%2E+Adler%22">Sharon G. Adler</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Kidney Research and Clinical Practice, Vol 41, Iss Suppl 2, Pp S63-S73 (2022)
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: The Korean Society of Nephrology, 2022.
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2022
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: LCC:Internal medicine<br />LCC:Specialties of internal medicine
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22chronic+kidney+diseases%22">chronic kidney diseases</searchLink><br /><searchLink fieldCode="DE" term="%22diabetic+kidney+disease%22">diabetic kidney disease</searchLink><br /><searchLink fieldCode="DE" term="%22end-stage+kidney+disease%22">end-stage kidney disease</searchLink><br /><searchLink fieldCode="DE" term="%22glucagon-like+peptide-1+receptor%22">glucagon-like peptide-1 receptor</searchLink><br /><searchLink fieldCode="DE" term="%22mineralocorticoid+receptor+antagonists%22">mineralocorticoid receptor antagonists</searchLink><br /><searchLink fieldCode="DE" term="%22renin-angiotensin-system%22">renin-angiotensin-system</searchLink><br /><searchLink fieldCode="DE" term="%22sodium-glucose+transporter+2+inhibitors%22">sodium-glucose transporter 2 inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+medicine%22">Internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22RC31-1245%22">RC31-1245</searchLink><br /><searchLink fieldCode="DE" term="%22Specialties+of+internal+medicine%22">Specialties of internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22RC581-951%22">RC581-951</searchLink>
– Name: Abstract
  Label: Description
  Group: Ab
  Data: Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease and end-stage kidney disease worldwide, as the obesity epidemic and the burden of diabetes continue to rise globally. In general, guideline management of patients with DKD recommends lifestyle modifications, blood pressure and glycemic control, and dyslipidemia treatment along with other cardiovascular disease risk reduction measures. The inhibition of the renin-angiotensin system (RAS) using an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker remains the foundational therapy for DKD. In type 2 diabetes (T2D), significant advances in therapeutics, including the sodium-glucose cotransporter-2 inhibitors (SGLT2i), the glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the nonsteroidal mineralocorticoid receptor agonist (MRA) finerenone, have dramatically expanded the armamentarium for treating DKD and its cardiovascular complications. Initiating, optimizing, and sustaining evidence-based pharmacological therapy using a therapeutic combination of RAS inhibitor + SGLT2i/GLP-1 RA + nonsteroidal MRA + statin is likely to significantly improve outcomes for T2D with DKD. Research into potential novel therapeutic targets for DKD remains particularly active and brings much anticipation and optimism to this field.
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article
– Name: Format
  Label: File Description
  Group: SrcInfo
  Data: electronic resource
– Name: Language
  Label: Language
  Group: Lang
  Data: English<br />Korean
– Name: ISSN
  Label: ISSN
  Group: ISSN
  Data: 2211-9132<br />2211-9140
– Name: NoteTitleSource
  Label: Relation
  Group: SrcInfo
  Data: http://www.krcp-ksn.org/upload/pdf/j-krcp-21-288.pdf; https://doaj.org/toc/2211-9132; https://doaj.org/toc/2211-9140
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.23876/j.krcp.21.288
– Name: URL
  Label: Access URL
  Group: URL
  Data: <link linkTarget="URL" linkTerm="https://doaj.org/article/682ffe0ab0b745c0956623929112495d" linkWindow="_blank">https://doaj.org/article/682ffe0ab0b745c0956623929112495d</link>
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsdoj.682ffe0ab0b745c0956623929112495d
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.682ffe0ab0b745c0956623929112495d
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.23876/j.krcp.21.288
    Languages:
      – Text: English
      – Text: Korean
    PhysicalDescription:
      Pagination:
        StartPage: S63
    Subjects:
      – SubjectFull: chronic kidney diseases
        Type: general
      – SubjectFull: diabetic kidney disease
        Type: general
      – SubjectFull: end-stage kidney disease
        Type: general
      – SubjectFull: glucagon-like peptide-1 receptor
        Type: general
      – SubjectFull: mineralocorticoid receptor antagonists
        Type: general
      – SubjectFull: renin-angiotensin-system
        Type: general
      – SubjectFull: sodium-glucose transporter 2 inhibitors
        Type: general
      – SubjectFull: Internal medicine
        Type: general
      – SubjectFull: RC31-1245
        Type: general
      – SubjectFull: Specialties of internal medicine
        Type: general
      – SubjectFull: RC581-951
        Type: general
    Titles:
      – TitleFull: Diabetic kidney disease treatment: new perspectives
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Li-Li Tong
      – PersonEntity:
          Name:
            NameFull: Sharon G. Adler
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 22119132
            – Type: issn-print
              Value: 22119140
          Numbering:
            – Type: volume
              Value: 41
            – Type: issue
              Value: Suppl 2
          Titles:
            – TitleFull: Kidney Research and Clinical Practice
              Type: main
ResultId 1